companydata.dkcompanydata.dk

CONTERA PHARMA A/S: Financial statements 2013

CVR: 33062214

Source: annual report 2013, Danish Business Authority

01/01/201331/12/2013

CONTERA PHARMA A/S (CVR 33062214) has filed annual accounts for 2013. In 2013, the company reported a gross profit of DKK -3,423,079 and a net result of DKK -4,726,146 compared with DKK -4,245,465 the year before. Equity in the 2013 report amounted to DKK 1,675,540. The solvency ratio was 40.8%.

Gross Profit
DKK -3,423,079
Profit/Loss
DKK -4,726,146
Equity
DKK 1,675,540
Total Assets
DKK 4,111,142

Development

YearRevenueGross ProfitProfit/LossEquityEmployees
2013--3.4 mio.-4.7 mio.1.7 mio.-
2012--3.7 mio.-4.2 mio.6.4 mio.-

Official annual report

View the official annual report directly on the page with a Pro subscription.

Fetch this data via API

Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.

See the API documentation

Events in 2013

Else Sissel Vorstrup joins the board of CONTERA PHARMA A/SNov 19, 2013

As of November 19, 2013, Else Sissel Vorstrup has joined the board of directors of CONTERA PHARMA A/S.

Joseph Donald deBethizy joins the board of CONTERA PHARMA A/SNov 19, 2013

As of November 19, 2013, Joseph Donald deBethizy has joined the board of directors of CONTERA PHARMA A/S.

John Bondo Hansen leaves the board of CONTERA PHARMA A/SNov 19, 2013

As of November 19, 2013, John Bondo Hansen has left the board of directors of CONTERA PHARMA A/S.

CONCIT PHARMA ApS changes name to CONTERA PHARMA ApSNov 19, 2013

On November 19, 2013, the company changed its name from CONCIT PHARMA ApS to CONTERA PHARMA ApS.

CONTERA PHARMA A/S: The 2012 annual report is outJun 3, 2013

CONTERA PHARMA A/S has published its annual report for 2012. Gross profit came to DKK -3,689,746, and the net result was DKK -4,245,465.

About CONTERA PHARMA A/S

CONTERA PHARMA A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2010. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named CONTERA PHARMA ApS and CONCIT PHARMA ApS. The management consists of Thomas Nikolaj Sager. The board consists of Jae Young Lee (chair), Jee Hun Kim, Paul Ejnar Gremaud Kristjansen and Thomas Nikolaj Sager. The company is owned by Bukwang Pharmaceutical Co., Ltd. The company has 1 employee (2018). In 2025, the company reported a gross profit of DKK 20,632,306 and a net result of DKK -4,783,781 compared with DKK -69,213,744 the year before. Equity in the 2025 report amounted to DKK 79,471,802.

Source: annual report 2025, Danish Business Authority